<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00500500</url>
  </required_header>
  <id_info>
    <org_study_id>2-29-00240-127</org_study_id>
    <nct_id>NCT00500500</nct_id>
  </id_info>
  <brief_title>Effect of EGb 761® on Patients With Mild to Moderate Alzheimer's Disease</brief_title>
  <official_title>Effect of EGb 761® on the Ratio of the Isoforms of the Protein Precursor of Beta Amyloid Platelets on Patients With Mild to Moderate Alzheimer's Disease. A Phase II, Randomised, Double-blind Trial, on Parallel Groups Versus Placebo.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <brief_summary>
    <textblock>
      The aim of this study is to measure the effect of EGb 761® versus placebo on the ratio of the
      isoform of the protein precursor of beta amyloid platelets, in patients with mild to moderate
      Alzheimer's disease.
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Inability to recruit sufficient number of patients
  </why_stopped>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">April 2008</completion_date>
  <primary_completion_date type="Actual">April 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Effect of EGb 761® on the ratio of the isoform of the protein precursor of beta amyloid platelets.</measure>
    <time_frame>Every visit</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Efficacy of EGb 761® on the cognitive functions and safety of EGb 761® at a dosage of 240 mg per day</measure>
    <time_frame>Every visit</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Alzheimer Disease</condition>
  <arm_group>
    <arm_group_label>EGb 761® (Tanakan®)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>EGb 761® (Tanakan®)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EGb 761® (Tanakan®)</intervention_name>
    <arm_group_label>EGb 761® (Tanakan®)</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  female or male of 50 to 85 years old with a care giver

          -  Mini Mental Status (MMS) test between 16 to 26 inclusive

          -  Clinical Dementia Rating (CDR) test inferior or equal to 1

          -  National Institute of Neurological and Communicative Disorders and Stroke /
             Alzheimer's Disease and Related Disorders Association (NINCDS/ADRDA) test positive for
             an Alzheimer's disease

          -  Diagnostic and Statistical Manual of Mental Disorders, 4th Edition (DSM IV) test
             positive for dementia

        Exclusion Criteria:

          -  patient already treated by medicines which could interfere with the study

          -  low level of vitamin B12 and folate which are considered as clinically relevant

          -  clinically relevant pathologies (eg: pulmonary illness, cardiovascular illness;
             evolutive cancer, neurological illness, blood illness….)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hôpital La Timone</name>
      <address>
        <city>Marseille</city>
        <zip>13 005</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>October 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 11, 2007</study_first_submitted>
  <study_first_submitted_qc>July 11, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2007</study_first_posted>
  <last_update_submitted>October 10, 2013</last_update_submitted>
  <last_update_submitted_qc>October 10, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 11, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

